Page 7 - David Berd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article FN Media Group Presents USA News Group News Commentary VANCOUVER, BC, March 12, 2021 /PRNewswire/ -- USA News Group  -  Rollouts of two approved COVID-19 vaccines have for the past few months started making their way into markets around the world. Amid the attention given to COVID vaccines, new vaccines that target different types of cancers are gaining momentum. In the UK, enthusiasm has been growing for a four-year-old girl attempting to raise £100,000 in less than four months for a potentially life-saving cancer vaccine. Thanks to growing acceptance towards the use...

BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants VANCOUVER, B.C., March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:

Share this article Share this article USD$900,000 In-Kind Investment by Procare Health into Phase I Clinical Study for BVX-0918A in the EU Co-Development of Vaccines for Cervical Cancer and HPV Right of First Refusal for US Marketing of Papilocare™ VANCOUVER, BC and BARCELONA, Spain, Feb. 10, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)  ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, and Procare Health Iberia, S.L., of Barcelona, Spain ("Procare Health"), a leading privately-held European pharmace...

Glenmede Investment Management Celebrates 5th Anniversary for Women in Leadership U.S. Equity Strategy Glenmede Investment Management Celebrates 5th Anniversary for Women in Leadership U.S. Equity Strategy Glenmede Investment Management LP (GIM), a privately owned, independent asset management firm, recently celebrated the five-year anniversary of its Glenmede Women in Leadership US Equity Strategy (Strategy). With more than $25.6 million in assets under management as of September 30, 2020, the strategy is a portfolio of large cap stocks, constructed with proprietary multi-factor models, bas...

Close (Photo : BioVaxys: "Back to the Future" ) BioVaxys, a clinical-stage biopharma group, are excelling in the development of antiviral and anticancer immunotherapeutics. Their speciality? A haptenized antigen vaccine platform. Haptenization stimulates a robust immune response, as it "teaches" the patient's immune system to recognise the target viral or tumor antigens as foreign. But how does it achieve this? The process of haptenization involves the modification of tumor cells, it's viral proteins, with a 'hapten' molecule. A hapten is a small chemical that is capable of tightly binding t...